Why the study?
Is Impella 2.5 support feasible and safe in patients with severe aortic valve stenosis and cardiogenic shock following emergency percutaneous balloon aortic valvuloplasty?
Is Impella 2.5 support feasible and safe in patients with severe aortic valve stenosis and cardiogenic shock following emergency percutaneous balloon aortic valvuloplasty?
Impella 2.5 support is feasible in patients with severe aortic stenosis and cardiogenic shock following emergency balloon aortic valvuloplasty, though 30-day mortality remains high.
May support Impella use after emergency BAV in severe AS shock; leaves open survival benefit and need for prospective trials.
BACKGROUND: To investigate the feasibility and outcomes of Impella 2.5 support in patients with severe aortic valve stenosis (AS) and cardiogenic shock (CS), who underwent emergency percutaneous balloon aortic valvuloplasty (BAV) with or without percutaneous coronary intervention (PCI). METHODS AND RESULTS: We retrospectively analyzed a consecutive series of patients with severe AS and CS who underwent Impella 2.5 support following emergency BAV with or without subsequent PCI. Outcome data included 30-day outcomes, periprocedural as well as throughout the circulatory support period complications. Eight patients with severe AS and CS were identified. Impella 2.5 implantation was successful following emergency BAV in all patients attempted. Additional PCI was performed in four patients. No periprocedural deaths or periprocedural neurologic events occurred. Mean procedure time was 125.9 min (range 64-210 min). Mortality at 30 days was 50%. CONCLUSIONS: Impella 2.5 can be used as hemodynamic support in patients with severe AS and CS following emergency percutaneous BAV and may help to improve tolerability of PCI in these high-risk patients.
No takes yet. Share an insight, caveat, or question.
Karatolios et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: